Wasserman Scott M.
SEC insider (Form 3/4/5 filer). CIK 0002118767. Director at Inhibikase Therapeutics, Inc. (IKT) and 1 other issuer. 3 reported Form 4/5 transactions since Sep 2024; latest on Oct 19, 2026. Located in WILMINGTON, DE.
Companies Wasserman Scott M. has filed insider reports for
- Inhibikase Therapeutics, Inc. (IKT): Director
- Kailera Therapeutics, Inc. (KLRA): Officer, Chief Medical Officer
Wasserman Scott M.
CIK: 0002118767
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)3 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (3 total)
- Oct 19, 2026IKT
Inhibikase Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
310K shares- - Apr 16, 2026KLRA
Kailera Therapeutics, Inc.
AwardDirectStock Option (right to buy)
100K shares- - Apr 16, 2026KLRA
Kailera Therapeutics, Inc.
AwardDirectStock Option (right to buy)
100K shares-
1-3 of 3 transactions